1-20 of 26
Jad Othman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A- rearranged acute myeloid leukemia

Sun Loo, Nicola Potter, Adam Ivey, Jenny O’Nions, Roderick Moon, Jelena Jovanovic, Chun Y. Fong, Natasha S. Anstee, Ing Soo Tiong, Jad Othman, Chong Chyn Chua, Hanna Renshaw, Robert Baker, Shaun Fleming, Nigel H. Russell, David Ritchie, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei
Journal: Blood
Blood (2024) 144 (24): 2554–2557.
https://doi.org/10.1182/blood.2024026605
Published: 2024
Includes: Supplemental data
Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Jad Othman, Nicola Potter, Sylvie D Freeman, Nicholas McCarthy, Jelena Jovanovic, Manohursingh Runglall, Joanna Canham, Ian Thomas, Sean Johnson, Jamie Cavenagh, Panagiotis Kottaridis, David Taussig, Claire Arnold, Claire Hemmaway, Dominic J. Culligan, Ulrik Malthe Overgaard, Alan K. Burnett, Mike Dennis, Richard Dillon, Nigel H. Russell
Journal: Blood
Blood (2024) 144 (Supplement 1): 845.
https://doi.org/10.1182/blood-2024-201097
Published: 2024
Journal Articles

Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Sun Loo, Harry Iland, Ing Soo Tiong, David Westerman, Jad Othman, Paula Marlton, Chong Chyn Chua, Duncan Purtill, Hannah Rose, Shaun Fleming, Deepak Singhal, Anoop K Enjeti, William S. Stevenson, Teng Fong Ng, McCulloch Derek, Lachlin Vaughan, Robin Gasiorowski, Adam Ivey, Amanda Souza, Revati Pattani, Natasha S. Anstee, Rachel Koldej, David S. Ritchie, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Andrew W. Roberts, Carolyn S. Grove, John Reynolds, Andrew H Wei
Journal: Blood
Blood (2024) 144 (Supplement 1): 223.
https://doi.org/10.1182/blood-2024-202895
Published: 2024
Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Chong Chyn Chua, Blake Hsu, Anoop K Enjeti, Ashish Bajel, Paula Marlton, Shaun Fleming, Devendra Hiwase, Chun Kei Kris Ma, Peter J. Browett, Travis Perera, Carolyn S. Grove, Shuhying Tan, Jad Othman, Julian Cooney, Hannah Rose, Edward S Morris, Rachel Koldej, David S. Ritchie, Kate Mason, Natasha S. Anstee, John Reynolds, Andrew H Wei
Journal: Blood
Blood (2024) 144 (Supplement 1): 217.
https://doi.org/10.1182/blood-2024-199882
Published: 2024
Journal Articles

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

Curtis A. Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N. Saultz, Jeffrey W. Tyner, Richard James Dillon, Joshua F. Zeidner, Daniel A. Pollyea
Journal: Blood
Blood blood.2024026925.
https://doi.org/10.1182/blood.2024026925
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Clinical Trials & Observations
Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D. Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D’Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H. Russell, Richard Dillon
Journal: Blood
Blood (2024) 144 (7): 714–728.
https://doi.org/10.1182/blood.2024024310
Published: 2024
Includes: Supplemental data
Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Clinical Trials & Observations Brief Report
Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D. Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel H. Russell
Journal: Blood
Blood (2024) 143 (19): 1931–1936.
https://doi.org/10.1182/blood.2023023096
Published: 2024
Includes: Supplemental data
Journal Articles

Molecular MRD is strongly prognostic in patients with NPM1 -mutated AML receiving venetoclax-based nonintensive therapy

Clinical Trials & Observations Brief Report
Jad Othman, Ing S. Tiong, Jenny O'Nions, Mike Dennis, Katya Mokretar, Adam Ivey, Michael Austin, Anne-Louise Latif, Mariam Amer, Wei Yee Chan, Charles Crawley, Francesca Crolla, Joe Cross, Ray Dang, Johnathon Elliot, Chun Y. Fong, Sofia Galli, Paolo Gallipoli, Francesca Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Sun Loo, Scott Marshall, Priyanka Mehta, Vidhya Murthy, Sateesh Nagumantry, Srinivas Pillai, Nicola Potter, Rob Sellar, Tom Taylor, Rui Zhao, Nigel H. Russell, Andrew H. Wei, Richard Dillon
Journal: Blood
Blood (2024) 143 (4): 336–341.
https://doi.org/10.1182/blood.2023021579
Published: 2024
Includes: Supplemental data
Journal Articles

Pre-Transplant Measurable Residual Disease (MRD) Detection of KMT2A- rearranged Acute Myeloid Leukemia Is Strongly Associated with Inferior Post-Transplant Outcome

Sun Loo, Nicola Potter, Adam Ivey, Jenny O'Nions, Roderick Moon, Chun Yew Fong, Natasha Anstee, Ing Soo Tiong, Chong Chyn Chua, Jad Othman, Hannah Renshaw, Robert Baker, Nigel H. Russell, Ashish Bajel, Hsin-An Hou, Richard Dillon, Andrew H. Wei
Journal: Blood
Blood (2023) 142 (Supplement 1): 1577.
https://doi.org/10.1182/blood-2023-185541
Published: 2023
Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell
Journal: Blood
Blood (2023) 142 (Supplement 1): 425.
https://doi.org/10.1182/blood-2023-179033
Published: 2023
Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Brian Huntly, Alan K. Burnett, Richard Dillon, Nigel Russell
Journal: Blood
Blood (2023) 142 (Supplement 1): 2939.
https://doi.org/10.1182/blood-2023-179036
Published: 2023
Journal Articles

Overlapping features of therapy-related and de novo NPM1 -mutated AML

Clinical Trials & Observations
Jad Othman, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard Schlenk, Richard Dillon, Sebastian Stasik, Alessandra Venanzi, Sarah Bertoli, Eric Delabesse, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Amanda F. Gilkes, Ian Thomas, Maria Teresa Voso, Alessandro Rambaldi, Lorenzo Brunetti, Vincenzo M. Perriello, Vibeke Andresen, Bjorn T. Gjertsen, Maria Paola Martelli, Christian Récher, Christoph Röllig, Martin Bornhäuser, Hubert Serve, Carsten Müller-Tidow, Claudia D. Baldus, Tortsten Haferlach, Nigel Russell, Brunangelo Falini
Journal: Blood
Blood (2023) 141 (15): 1846–1857.
https://doi.org/10.1182/blood.2022018108
Published: 2023
Includes: Supplemental data
Journal Articles

Pretransplant FLT3 -ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

Sun Loo, Richard Dillon, Adam Ivey, Natasha S. Anstee, Jad Othman, Ing Soo Tiong, Nicola Potter, Jelena Jovanovic, Manohursingh Runglall, Chyn Chua Chong, Ashish Bajel, David Ritchie, Kelli Gray, Zhi Han Yeoh, Michelle McBean, Amanda Gilkes, Ian Thomas, Sean Johnson, Nigel H. Russell, Andrew H. Wei
Journal: Blood
Blood (2022) 140 (22): 2407–2411.
https://doi.org/10.1182/blood.2022016567
Published: 2022
Includes: Supplemental data
Journal Articles

Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy

Jad Othman, Ing S Tiong, Katya Mokretar, Adam Ivey, Michael James Austin, Anne-Louise Latif, Charles Crawley, Mariam Amer, Francesca Crolla, Joe W Cross, Raymond Dang, Chun Yew Fong, Sofia Galli, Paolo Gallipoli, Francesca L Hogan, Pallavi Kalkur, Anjum Khan, Pramila Krishnamurthy, John Laurie, Scott R. Marshall, Vidhya Murthy, Sateesh K. Nagumantry, Srinivas Pillai, Nicola Potter, Tom Taylor, Rui Zhao, Andrew H Wei, Richard Dillon
Journal: Blood
Blood (2022) 140 (Supplement 1): 2033–2035.
https://doi.org/10.1182/blood-2022-159467
Published: 2022
Journal Articles

Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease - Real-World Data from a UK-Wide Programme

Henry Wood, Christianne Bourlon, Austin Kulasekararaj, Albert Borg, Jiri Pavlu, Patrick Elder, David C Taussig, Scott Veitch, Steven Knapper, Jad Othman, Richard Dillon, James Aries, Emily Mitchell, Faisal Basheer, Steven Leak, Vidhya Murthy, Joe W Cross, Priyanka Mehta, Manish Jain, Anjum Khan, Ho Lam, Sarah Leong, Jenny O'Nions, Charles Craddock, Victoria Potter, Mhairi Copland, Pramila Krishnamurthy
Journal: Blood
Blood (2022) 140 (Supplement 1): 9016–9018.
https://doi.org/10.1182/blood-2022-167097
Published: 2022
Journal Articles

Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1 m Patients Achieving MRD-Negative CR after Intensive Induction

Konstanze Döhner, Hartmut Döhner, Daniela Weber, Silke Kapp-Schwoerer, Amanda Gilkes, Ian Thomas, Sean Johnson, Nicola Potter, Yana Bevan, Jad Othman, Nigel H. Russell, Christoph Röllig, Christian Thiede, Martin Bornhaeuser, Thomas Oellerich, Jenna Elder, Luis A. Carvajal, Zung To, Jorge DiMartino, Richard Dillon
Journal: Blood
Blood (2022) 140 (Supplement 1): 6293–6294.
https://doi.org/10.1182/blood-2022-159212
Published: 2022
Journal Articles

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Jad Othman, Richard Dillon, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panos Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell
Journal: Blood
Blood (2022) 140 (Supplement 1): 1036–1038.
https://doi.org/10.1182/blood-2022-159433
Published: 2022
Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis
Journal: Blood
Blood (2022) 140 (Supplement 1): 526–528.
https://doi.org/10.1182/blood-2022-162377
Published: 2022
Journal Articles

High Molecular Response Rate and Overall Survival with FLT3 Inhibitors As MRD-Guided Salvage Treatment for Molecular Failure in AML

Jad Othman, Nicola Potter, Katya Mokretar, David Taussig, Anjum Khan, Pramila Krishnamurthy, Anne-Louise Latif, Paul Cahalin, James Aries, Mariam Amer, Edward Belsham, Eibhlin Conneally, Charles Craddock, Dominic Culligan, Mike Dennis, Caroline Duncan, Caroline Furness, Paraskevi Gkreka, Katherine Hodgson, Wendy Ingram, Andrew King, Panagiotis Kottaridis, Mary Frances McMullin, Unmesh Mohite, Loretta Ngu, Katharine Patrick, Tom Rider, Wing Roberts, Marianne Tang Severinsen, Neill Storrar, Tom Taylor, Nigel H. Russell, Richard Dillon
Journal: Blood
Blood (2022) 140 (Supplement 1): 2002–2004.
https://doi.org/10.1182/blood-2022-159503
Published: 2022
Journal Articles

Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

Luis A. Carvajal, Tressa Hood, Yana Bevan, Richard Dillon, Nicola Potter, Ian Thomas, Sean Johnson, Jad Othman, Amanda Gilkes, Nigel H. Russell, Adam Sikorski, Pete Ellis, Giovanni Marsico, Greg Jones, Crystal MacKenzie, Zung To, Jorge DiMartino, Pavan Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 3377–3378.
https://doi.org/10.1182/blood-2022-159154
Published: 2022